<![CDATA[Stories in Life Sciences]]>Stories in Life Sciences explores the people, technologies, and strategies transforming how ideas move from discovery to real-world impact in healthcare.

Presented by MedAxis AI, each episode features candid conversations with founders, scientists, investors, and commercialization leaders from across Biotech, MedTech, Pharma, and Digital Health. From reimagining surgical tools and personalizing neonatal care with AI, to pioneering predictive ophthalmology and developing bioabsorbable implants — we go behind the scenes of the breakthroughs shaping modern medicine.

Every conversation bridges commercialization strategy, ethical AI, and human-centered storytelling to uncover how visionary ideas become real-world impact.

Whether you're a startup founder, life sciences professional, investor, or simply curious about the future of healthcare innovation, this podcast is your front-row seat to the stories that matter.

Subscribe for new episodes and visit medaxisai.org to learn more.

]]>https://medaxisai.org/podcastRiverside.fm (https://riverside.com)Sun, 05 Apr 2026 18:21:45 GMTMon, 23 Mar 2026 19:50:18 GMT60Christopher Wilson<p>Stories in Life Sciences explores the people, technologies, and strategies transforming how ideas move from discovery to real-world impact in healthcare.</p><p></p><p>Presented by MedAxis AI, each episode features candid conversations with founders, scientists, investors, and commercialization leaders from across Biotech, MedTech, Pharma, and Digital Health. From reimagining surgical tools and personalizing neonatal care with AI, to pioneering predictive ophthalmology and developing bioabsorbable implants — we go behind the scenes of the breakthroughs shaping modern medicine.</p><p></p><p>Every conversation bridges commercialization strategy, ethical AI, and human-centered storytelling to uncover how visionary ideas become real-world impact.</p><p></p><p>Whether you're a startup founder, life sciences professional, investor, or simply curious about the future of healthcare innovation, this podcast is your front-row seat to the stories that matter.</p><p></p><p>Subscribe for new episodes and visit <a rel="noopener noreferrer nofollow" href="http://medaxisai.org" target="_blank">medaxisai.org</a> to learn more.</p>episodicChristopher Wilsonchristopher@medaxisai.orgno<![CDATA[Nikole Kimes: Preventing Allergic Disease From Birth | Stories in Life Sciences]]>Can the gut microbiome in the first year of life determine whether a child develops allergies, asthma, or atopic dermatitis? 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nikole Kimes, Ph.D., Co-Founder and CEO of Siolta Therapeutics, to explore the clinical evidence behind early-life microbiome intervention and what it means for the future of allergic disease prevention.

Nikole spent years studying microbial ecosystems in coral reefs before applying ecological systems thinking to the human gut. Siolta Therapeutics recently completed a Phase 2 proof-of-concept study using a defined bacterial consortia given orally in the first year of life. Results showed a 64% reduction in atopic dermatitis and a 77% reduction in food allergy, with durability past the treatment period.

We cover:

  • How the developing infant gut microbiome is linked to allergic disease risk
  • Siolta Therapeutics' Phase 2 clinical results for atopic dermatitis and food allergy prevention
  • How a defined bacterial consortia is formulated from clinical data and functional optimization
  • Why the first year of life is the critical immune training window for allergic disease
  • The reimbursement and funding challenges unique to prevention drug development
  • How GLP-1s and HIV PrEP demonstrate that prevention medicine can be economically viable
  • What a Phase 3 pivotal study and BLA pathway looks like for a new prevention modality
  • Nikole's advice for founders navigating a system not designed for prevention

Who this is for: life sciences founders, biotech investors, clinical researchers, and healthcare professionals interested in the microbiome, early-life disease prevention, and the future of immune modulation therapies.

Guest:

Nikole Kimes, Ph.D.

Co-Founder and CEO, Siolta Therapeutics

https://www.sioltatherapeutics.com

https://www.linkedin.com/in/nikole-kimes-4b357786 https://www.linkedin.com/company/siolta-therapeutics


]]>6c102f7e-22d9-420b-ade7-c8e1c2722e42Wed, 01 Apr 2026 06:04:40 GMT<p>Can the gut microbiome in the first year of life determine whether a child develops allergies, asthma, or atopic dermatitis? </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Nikole Kimes, Ph.D., Co-Founder and CEO of Siolta Therapeutics, to explore the clinical evidence behind early-life microbiome intervention and what it means for the future of allergic disease prevention.</p><p></p><p>Nikole spent years studying microbial ecosystems in coral reefs before applying ecological systems thinking to the human gut. Siolta Therapeutics recently completed a Phase 2 proof-of-concept study using a defined bacterial consortia given orally in the first year of life. Results showed a 64% reduction in atopic dermatitis and a 77% reduction in food allergy, with durability past the treatment period.</p><p></p><p>We cover:</p><ul><li>How the developing infant gut microbiome is linked to allergic disease risk</li><li>Siolta Therapeutics' Phase 2 clinical results for atopic dermatitis and food allergy prevention</li><li>How a defined bacterial consortia is formulated from clinical data and functional optimization</li><li>Why the first year of life is the critical immune training window for allergic disease</li><li>The reimbursement and funding challenges unique to prevention drug development</li><li>How GLP-1s and HIV PrEP demonstrate that prevention medicine can be economically viable</li><li>What a Phase 3 pivotal study and BLA pathway looks like for a new prevention modality</li><li>Nikole's advice for founders navigating a system not designed for prevention<p></p></li></ul><p>Who this is for: life sciences founders, biotech investors, clinical researchers, and healthcare professionals interested in the microbiome, early-life disease prevention, and the future of immune modulation therapies.</p><p></p><p>Guest: </p><p>Nikole Kimes, Ph.D.</p><p>Co-Founder and CEO, Siolta Therapeutics</p><p><a rel="noopener noreferrer nofollow" href="https://www.sioltatherapeutics.com" target="_blank">https://www.sioltatherapeutics.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/nikole-kimes-4b357786" target="_blank">https://www.linkedin.com/in/nikole-kimes-4b357786</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/siolta-therapeutics" target="_blank"> https://www.linkedin.com/company/siolta-therapeutics</a></p><p><br /></p>no00:39:28122Nikole Kimes: Preventing Allergic Disease From Birth | Stories in Life Sciencesfull<![CDATA[Michael Howell The Gap Between a Drug and a Product Stories in Life Sciences]]>What separates a promising drug from a commercial product runs deeper than the science. 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Howell, Founder and President of Mountaineer Biosciences, to explore what it actually takes to move from scientific discovery to a commercially viable drug development strategy.

Michael has spent 20+ years moving between academic research, big pharma, and early-stage biotech, co-inventing drugs like Skyrizi, helping build Incyte Dermatology, and serving as CSO for two publicly traded companies. Today at Mountaineer Biosciences, he works with venture firms, investment banks, and early-stage companies to bridge the gap between scientific discovery and commercialization strategy.

We cover:

  • How the transition from academic research to industry actually works
  • What scientists miss when they first encounter commercial drug development
  • The Lombard Street framework: finding the straight path in drug development
  • How pharma deals are actually made and what the due diligence process reveals
  • What AI can and cannot do in drug discovery today
  • Resetting the immune system: combinatorial approaches to autoimmune disease
  • How Mountaineer Biosciences helps early-stage companies find their commercial focus
  • Advice for scientists navigating the transition from research to commercialization

Who this is for: life sciences founders, scientists considering the transition to industry, and early-stage biotech operators looking to sharpen their commercialization strategy.

Guest:

Michael Howell

Founder and President, Mountaineer Biosciences 

https://mountaineerbiosciences.com 

https://www.linkedin.com/in/michael-howell-357b1416https://www.linkedin.com/company/mountaineer-biosciences-inc

Host:

Christopher Wilson

Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>80e7f66e-7323-4c30-b2b0-c06cb9efd331Wed, 01 Apr 2026 06:01:01 GMT<p>What separates a promising drug from a commercial product runs deeper than the science. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Howell, Founder and President of Mountaineer Biosciences, to explore what it actually takes to move from scientific discovery to a commercially viable drug development strategy.</p><p></p><p>Michael has spent 20+ years moving between academic research, big pharma, and early-stage biotech, co-inventing drugs like Skyrizi, helping build Incyte Dermatology, and serving as CSO for two publicly traded companies. Today at Mountaineer Biosciences, he works with venture firms, investment banks, and early-stage companies to bridge the gap between scientific discovery and commercialization strategy.</p><p></p><p>We cover:</p><ul><li>How the transition from academic research to industry actually works</li><li>What scientists miss when they first encounter commercial drug development</li><li>The Lombard Street framework: finding the straight path in drug development</li><li>How pharma deals are actually made and what the due diligence process reveals</li><li>What AI can and cannot do in drug discovery today</li><li>Resetting the immune system: combinatorial approaches to autoimmune disease</li><li>How Mountaineer Biosciences helps early-stage companies find their commercial focus</li><li>Advice for scientists navigating the transition from research to commercialization<p></p></li></ul><p>Who this is for: life sciences founders, scientists considering the transition to industry, and early-stage biotech operators looking to sharpen their commercialization strategy.</p><p></p><p>Guest: </p><p>Michael Howell</p><p>Founder and President, Mountaineer Biosciences<a rel="noopener noreferrer nofollow" href="https://mountaineerbiosciences.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://mountaineerbiosciences.com" target="_blank">https://mountaineerbiosciences.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/michael-howell-357b1416" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/michael-howell-357b1416https://www.linkedin.com/company/mountaineer-biosciences-inc" target="_blank">https://www.linkedin.com/in/michael-howell-357b1416https://www.linkedin.com/company/mountaineer-biosciences-inc</a></p><p></p><p>Host:</p><p>Christopher Wilson</p><p>Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p><p></p>no00:44:03121Michael Howell The Gap Between a Drug and a Product Stories in Life Sciencesfull<![CDATA[Paul Davison Reimagining Open Surgery with Lamina Surgical Stories in Life Sciences]]>Open surgery accounts for a third of all surgical procedures. Paul Davison puts the market at 35 million cases in the U.S. annually, growing at 9% a year, and the core tool used in most of them dates to the 1920s. 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Paul Davison, CEO and Co-founder of Lamina Surgical, to explore what it looks like to reimagine open surgery with advanced electrosurgery and integrated imaging.

Paul has spent 30 years building medical devices at Baxter, Medtronic, ArthroCare, and Peak Surgical, which was acquired by Medtronic. He brings a founder's perspective that spans factory technician to CEO, and a deep understanding of how platform technologies evolve across clinical applications. At Lamina Surgical, he is building tools that combine electrosurgery with integrated imaging to give surgeons visibility they have not had before.

We cover:

  • Why the open surgery market represents 35 million U.S. procedures annually with minimal recent innovation
  • Electrosurgery history: from William Bovie at Harvard in 1928 to today's safety gaps
  • How Lamina Surgical combines electrosurgery and integrated imaging for open surgery
  • Platform technology pivots: how ArthroCare moved from coronary arteries to arthroscopy
  • Plasma blade origin: how Peak Surgical was born from a Stanford eye surgery concept
  • Seed-stage MedTech funding: navigating a difficult early-stage capital environment
  • How AI tools are helping lean founding teams replace early hires
  • Paul's journey from factory technician at Baxter to CEO at Lamina Surgical

Who this is for: founders and engineers in MedTech, open surgery, electrosurgery, surgical devices, and life sciences commercialization who want to understand how legacy clinical tools get reimagined.

Guest: 

Paul Davison

CEO and Co-founder, Lamina Surgical

www.laminasurgical.com

https://www.linkedin.com/in/paul-davison-medtechhttps://www.linkedin.com/company/lamina-surgical

Host:

Christopher Wilson

Founder, Medaxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>991e773a-0a40-40b3-a0ae-34101a90d729Wed, 01 Apr 2026 05:40:38 GMT<p>Open surgery accounts for a third of all surgical procedures. Paul Davison puts the market at 35 million cases in the U.S. annually, growing at 9% a year, and the core tool used in most of them dates to the 1920s. <br /></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Paul Davison, CEO and Co-founder of Lamina Surgical, to explore what it looks like to reimagine open surgery with advanced electrosurgery and integrated imaging.</p><p></p><p>Paul has spent 30 years building medical devices at Baxter, Medtronic, ArthroCare, and Peak Surgical, which was acquired by Medtronic. He brings a founder's perspective that spans factory technician to CEO, and a deep understanding of how platform technologies evolve across clinical applications. At Lamina Surgical, he is building tools that combine electrosurgery with integrated imaging to give surgeons visibility they have not had before.</p><p></p><p>We cover:</p><ul><li>Why the open surgery market represents 35 million U.S. procedures annually with minimal recent innovation</li><li>Electrosurgery history: from William Bovie at Harvard in 1928 to today's safety gaps</li><li>How Lamina Surgical combines electrosurgery and integrated imaging for open surgery</li><li>Platform technology pivots: how ArthroCare moved from coronary arteries to arthroscopy</li><li>Plasma blade origin: how Peak Surgical was born from a Stanford eye surgery concept</li><li>Seed-stage MedTech funding: navigating a difficult early-stage capital environment</li><li>How AI tools are helping lean founding teams replace early hires</li><li>Paul's journey from factory technician at Baxter to CEO at Lamina Surgical<p></p></li></ul><p>Who this is for: founders and engineers in MedTech, open surgery, electrosurgery, surgical devices, and life sciences commercialization who want to understand how legacy clinical tools get reimagined.</p><p></p><p>Guest: </p><p>Paul Davison</p><p>CEO and Co-founder, Lamina Surgical</p><p><a rel="noopener noreferrer nofollow" href="http://www.laminasurgical.com" target="_blank">www.laminasurgical.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/paul-davison-medtechhttps://www.linkedin.com/company/lamina-surgical" target="_blank">https://www.linkedin.com/in/paul-davison-medtechhttps://www.linkedin.com/company/lamina-surgical</a></p><p></p><p>Host:</p><p>Christopher Wilson</p><p>Founder, Medaxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:40:39120Paul Davison Reimagining Open Surgery with Lamina Surgical Stories in Life Sciencesfull<![CDATA[ Isabel Hoffmann Personalized Neonatal Nutrition and AI in the NICU Stories in Life Sciences]]>Premature baby nutrition in most NICUs is standardized: the same fortification dose for every infant, regardless of gestational age, weight, or clinical profile.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Isabel Hoffmann, CEO of TellSpec and Preemie Health, to explore how a 30-second human milk sensor and personalized AI prescriptions are changing neonatal care.

Isabel built a near-infrared spectroscopy sensor that analyzes human milk for fat, protein, and fatty acids in 30 seconds and generates a personalized fortification prescription matched to each premature baby's clinical data. Her path to neonatal AI ran through children's educational software and Apple bundling deals, giving her a founder's perspective that spans consumer tech and deep medical device development.

We cover:

  • Why standardized fortification over- or under-doses preterm infants and what personalized nutrition changes
  • How near-infrared spectroscopy analyzes human milk composition in 30 seconds
  • Federated learning in healthcare: training NICU AI models without sharing patient data across hospitals
  • How the FDA freeze-and-resubmit process works for AI model certification in medical devices
  • How TellSpec trained early models using synthetic data from peer-reviewed literature
  • The gap between developed and developing country NICU standards in neonatal intensive care
  • Why we know less about human milk than about erectile dysfunction and what that reveals about research priorities
  • Isabel's journey from children's educational software and Apple bundling deals to neonatal AI

Who this is for: founders and researchers in MedTech, neonatal care, digital health, AI in healthcare, and life sciences commercialization who want to understand how personalized nutrition and AI are changing outcomes in the NICU.

Guest:

Isabel Hoffmann, CEO, TellSpec and Preemie Health

https://tellspec.com 

https://www.preemiesensor.com 

https://www.linkedin.com/in/isabelhoffmann

https://www.linkedin.com/company/tellspec

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.


]]>37497838-2691-4689-b234-4a9bbf896e57Fri, 27 Mar 2026 12:29:39 GMT<p>Premature baby nutrition in most NICUs is standardized: the same fortification dose for every infant, regardless of gestational age, weight, or clinical profile.</p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Isabel Hoffmann, CEO of TellSpec and Preemie Health, to explore how a 30-second human milk sensor and personalized AI prescriptions are changing neonatal care.</p><p></p><p>Isabel built a near-infrared spectroscopy sensor that analyzes human milk for fat, protein, and fatty acids in 30 seconds and generates a personalized fortification prescription matched to each premature baby's clinical data. Her path to neonatal AI ran through children's educational software and Apple bundling deals, giving her a founder's perspective that spans consumer tech and deep medical device development.</p><p></p><p>We cover:</p><ul><li>Why standardized fortification over- or under-doses preterm infants and what personalized nutrition changes</li><li>How near-infrared spectroscopy analyzes human milk composition in 30 seconds</li><li>Federated learning in healthcare: training NICU AI models without sharing patient data across hospitals</li><li>How the FDA freeze-and-resubmit process works for AI model certification in medical devices</li><li>How TellSpec trained early models using synthetic data from peer-reviewed literature</li><li>The gap between developed and developing country NICU standards in neonatal intensive care</li><li>Why we know less about human milk than about erectile dysfunction and what that reveals about research priorities</li><li>Isabel's journey from children's educational software and Apple bundling deals to neonatal AI<p></p></li></ul><p>Who this is for: founders and researchers in MedTech, neonatal care, digital health, AI in healthcare, and life sciences commercialization who want to understand how personalized nutrition and AI are changing outcomes in the NICU.</p><p></p><p>Guest:</p><p>Isabel Hoffmann, CEO, TellSpec and Preemie Health</p><p><a rel="noopener noreferrer nofollow" href="https://tellspec.com" target="_blank">https://tellspec.com</a><a rel="noopener noreferrer nofollow" href="https://www.preemiesensor.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.preemiesensor.com" target="_blank">https://www.preemiesensor.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/isabelhoffmann" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/isabelhoffmann" target="_blank">https://www.linkedin.com/in/isabelhoffmann</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/tellspec" target="_blank">https://www.linkedin.com/company/tellspec</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p><br /></p>no00:44:34119 Isabel Hoffmann Personalized Neonatal Nutrition and AI in the NICU Stories in Life Sciencesfull<![CDATA[Leena Pradhan-Nabzdyk: Biological Testing Standards for Supplements | Stories in Life Sciences]]>What if the supplement you have been taking for years has never actually been tested in human cells? 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Leena Pradhan-Nabzdyk, Co-founder and CEO of Canomiks, to explore what standard chemical analysis misses and why biological testing at the cellular level changes what we know about supplement safety and efficacy.

Leena holds a PhD in pharmacology and an MBA from MIT Sloan, and spent years as a faculty investigator at Harvard Medical School focused on cardiovascular disease, diabetes, and wound healing. At Canomiks, she applies genomics and bioinformatics to the nutraceutical and dietary supplement industry, bringing biological rigor to ingredients that have been validated culturally for centuries but rarely tested at the cellular level. Canomiks is backed by an NSF grant exceeding $1 million and is building the biological batch-to-batch standards the supplement industry currently lacks.

We cover:

  • Why chemical analysis confirms the right compound is present but misses how it affects human gene expression
  • How the same turmeric at the same concentration can produce completely different biological effects
  • How Canomiks is building biological batch-to-batch standards for natural ingredients
  • What WhatToTrust.com is doing to help consumers evaluate supplements based on the science behind them
  • Leena's path from Harvard faculty to MIT Sloan MBA to biotech co-founder
  • How scientists can approach commercializing research in the nutraceutical and supplement space
  • Why the current validation bar for dietary supplements is not high enough

Who this is for: life sciences founders, biotech operators, researchers in genomics and nutraceuticals, and anyone who wants to understand what actually goes into validating a supplement at the biological level.

Guest:

Leena Pradhan-Nabzdyk

Co-founder and CEO, Canomiks 

https://www.canomiks.com

https://www.linkedin.com/in/leenapradhannabzdyk

https://www.linkedin.com/company/canomiks

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>62a27e1c-d002-4cf7-872c-74e0f344fcd7Fri, 27 Mar 2026 12:24:04 GMT<p>What if the supplement you have been taking for years has never actually been tested in human cells? </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Leena Pradhan-Nabzdyk, Co-founder and CEO of Canomiks, to explore what standard chemical analysis misses and why biological testing at the cellular level changes what we know about supplement safety and efficacy.</p><p></p><p>Leena holds a PhD in pharmacology and an MBA from MIT Sloan, and spent years as a faculty investigator at Harvard Medical School focused on cardiovascular disease, diabetes, and wound healing. At Canomiks, she applies genomics and bioinformatics to the nutraceutical and dietary supplement industry, bringing biological rigor to ingredients that have been validated culturally for centuries but rarely tested at the cellular level. Canomiks is backed by an NSF grant exceeding $1 million and is building the biological batch-to-batch standards the supplement industry currently lacks.</p><p></p><p>We cover:</p><ul><li>Why chemical analysis confirms the right compound is present but misses how it affects human gene expression</li><li>How the same turmeric at the same concentration can produce completely different biological effects</li><li>How Canomiks is building biological batch-to-batch standards for natural ingredients</li><li>What <a rel="noopener noreferrer nofollow" href="http://WhatToTrust.com" target="_blank">WhatToTrust.com</a> is doing to help consumers evaluate supplements based on the science behind them</li><li>Leena's path from Harvard faculty to MIT Sloan MBA to biotech co-founder</li><li>How scientists can approach commercializing research in the nutraceutical and supplement space</li><li>Why the current validation bar for dietary supplements is not high enough<p></p></li></ul><p>Who this is for: life sciences founders, biotech operators, researchers in genomics and nutraceuticals, and anyone who wants to understand what actually goes into validating a supplement at the biological level.</p><p></p><p>Guest:</p><p>Leena Pradhan-Nabzdyk</p><p>Co-founder and CEO, Canomiks<a rel="noopener noreferrer nofollow" href="https://www.canomiks.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.canomiks.com" target="_blank">https://www.canomiks.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/leenapradhannabzdyk" target="_blank">https://www.linkedin.com/in/leenapradhannabzdyk</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/canomiks" target="_blank">https://www.linkedin.com/company/canomiks</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a> <a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:42:20118Leena Pradhan-Nabzdyk: Biological Testing Standards for Supplements | Stories in Life Sciencesfull<![CDATA[Dr. Michael Cetta: Modernizing the EKG Process with Crimson Scientific | Stories in Life Sciences]]>Almost 2 million EKGs are performed every day worldwide. Every single one still requires ten wires, ten stickers, and hoping someone puts them in the right place.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Michael Cetta and Mark Zachary, Co-founders of Crimson Scientific, to explore how they are cutting EKG capture time in half and eliminating the complexity that leads to errors.

Dr. Cetta spent years running emergency departments, watching this same slow, error-prone process repeat itself thousands of times. Mark Zachary, a biomedical engineer who built AI tools at Boston Scientific and Mayo Clinic, saw the same inefficiency from the technology side. Together at Crimson Scientific, they are building a more accurate, faster EKG process designed for how clinical environments actually work.

We cover:

  • Why the EKG process has remained largely unchanged for 50 years despite daily use at scale
  • How Crimson Scientific is cutting EKG capture time in half and reducing placement errors
  • Why customer validation came before building the solution
  • The decision to build in-house rather than rely on contractors
  • The hidden challenge in MedTech: bridging clinical improvement to economic value
  • How M-Hub accelerated Crimson Scientific's path to commercialization
  • What it takes to modernize a standard used 2 million times daily worldwide

Who this is for: MedTech founders, clinicians, investors, and researchers in cardiology, medical devices, and healthcare AI who want to understand how established clinical standards get modernized.

Guests: 

Dr. Michael Cetta, MD FACEP FACHE

CEO and Co-founder

Mark Zachary

Co-founder

Crimson Scientific 

https://www.crimsonscientific.com

https://www.linkedin.com/in/michaelcetta

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>a8cf349c-6964-470b-8404-f8875cde22cdFri, 27 Mar 2026 12:02:47 GMT<p>Almost 2 million EKGs are performed every day worldwide. Every single one still requires ten wires, ten stickers, and hoping someone puts them in the right place.</p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Michael Cetta and Mark Zachary, Co-founders of Crimson Scientific, to explore how they are cutting EKG capture time in half and eliminating the complexity that leads to errors.</p><p></p><p>Dr. Cetta spent years running emergency departments, watching this same slow, error-prone process repeat itself thousands of times. Mark Zachary, a biomedical engineer who built AI tools at Boston Scientific and Mayo Clinic, saw the same inefficiency from the technology side. Together at Crimson Scientific, they are building a more accurate, faster EKG process designed for how clinical environments actually work.</p><p></p><p>We cover:</p><ul><li>Why the EKG process has remained largely unchanged for 50 years despite daily use at scale</li><li>How Crimson Scientific is cutting EKG capture time in half and reducing placement errors</li><li>Why customer validation came before building the solution</li><li>The decision to build in-house rather than rely on contractors</li><li>The hidden challenge in MedTech: bridging clinical improvement to economic value</li><li>How M-Hub accelerated Crimson Scientific's path to commercialization</li><li>What it takes to modernize a standard used 2 million times daily worldwide<p></p></li></ul><p>Who this is for: MedTech founders, clinicians, investors, and researchers in cardiology, medical devices, and healthcare AI who want to understand how established clinical standards get modernized.</p><p></p><p>Guests: </p><p>Dr. Michael Cetta, MD FACEP FACHE</p><p>CEO and Co-founder</p><p>Mark Zachary</p><p>Co-founder</p><p>Crimson Scientific<a rel="noopener noreferrer nofollow" href="https://www.crimsonscientific.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.crimsonscientific.com" target="_blank">https://www.crimsonscientific.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/michaelcetta" target="_blank">https://www.linkedin.com/in/michaelcetta</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.<br /></p>no00:41:45117Dr. Michael Cetta: Modernizing the EKG Process with Crimson Scientific | Stories in Life Sciencesfull<![CDATA[Vince Ehrenberg: Safer Bathroom Design for Aging Adults and Caregivers | Stories in Life Sciences]]>80% of serious accidents at home happen in the bathroom. Most of the equipment designed to prevent those accidents hasn't changed since the 1970s. 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vince Ehrenberg, Founder and Inventor of PeriChair, to explore what happens when a caregiver decides to solve the problem himself.

Vince became a full-time caregiver overnight when his father developed vascular dementia. What he found was a gap: bathroom safety equipment designed with everyone except the user in mind. Flat benches that don't feel safe. Transfer chairs you can't see around. Equipment that forces people to stand in soapy water just to stay clean. So he started building, moving from jerry-rigged prototypes with a saw and foam to a patented product now navigating Medicare reimbursement and medical device manufacturing.

One detail that stood out: his 90-year-old mother uses the chair now, and he hasn't had to give her one shower. That's what happens when you design from lived experience instead of a lab.

We cover:

  • Why the bathroom is the most dangerous room in the home for aging adults
  • How bathroom safety equipment has gone largely unchanged since the 1970s
  • Vince's journey from caregiver to inventor and medical device founder
  • How PeriChair was designed around the lived experience of patients and caregivers
  • The process of moving from prototype to patented product with no industry background
  • Navigating Medicare reimbursement as a first-time medical device founder
  • What the aging adult care market needs that current equipment isn't delivering

Who this is for: medical device founders, caregivers, clinicians, and investors in aging care, home health, and MedTech who want to understand how lived experience drives product innovation.

Guest: 

Vince Ehrenberg, Founder and Inventor, PeriChair 

www.perichair.com 

https://www.linkedin.com/in/vincent-ehrenberg-10037819a

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>2a250bba-fa84-44f2-b097-67e1ad89a338Fri, 27 Mar 2026 11:51:16 GMT<p>80% of serious accidents at home happen in the bathroom. Most of the equipment designed to prevent those accidents hasn't changed since the 1970s. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vince Ehrenberg, Founder and Inventor of PeriChair, to explore what happens when a caregiver decides to solve the problem himself.</p><p></p><p>Vince became a full-time caregiver overnight when his father developed vascular dementia. What he found was a gap: bathroom safety equipment designed with everyone except the user in mind. Flat benches that don't feel safe. Transfer chairs you can't see around. Equipment that forces people to stand in soapy water just to stay clean. So he started building, moving from jerry-rigged prototypes with a saw and foam to a patented product now navigating Medicare reimbursement and medical device manufacturing.</p><p>One detail that stood out: his 90-year-old mother uses the chair now, and he hasn't had to give her one shower. That's what happens when you design from lived experience instead of a lab.</p><p></p><p>We cover:</p><ul><li>Why the bathroom is the most dangerous room in the home for aging adults</li><li>How bathroom safety equipment has gone largely unchanged since the 1970s</li><li>Vince's journey from caregiver to inventor and medical device founder</li><li>How PeriChair was designed around the lived experience of patients and caregivers</li><li>The process of moving from prototype to patented product with no industry background</li><li>Navigating Medicare reimbursement as a first-time medical device founder</li><li>What the aging adult care market needs that current equipment isn't delivering<p></p></li></ul><p>Who this is for: medical device founders, caregivers, clinicians, and investors in aging care, home health, and MedTech who want to understand how lived experience drives product innovation.</p><p></p><p>Guest: </p><p>Vince Ehrenberg, Founder and Inventor, PeriChair<a rel="noopener noreferrer nofollow" href="http://www.perichair.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="http://www.perichair.com" target="_blank">www.perichair.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/vincent-ehrenberg-10037819a" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/vincent-ehrenberg-10037819a" target="_blank">https://www.linkedin.com/in/vincent-ehrenberg-10037819a</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.<br /></p>no00:28:54116Vince Ehrenberg: Safer Bathroom Design for Aging Adults and Caregivers | Stories in Life Sciencesfull<![CDATA[Manuel Opitz: Predictive AI in Ophthalmology and Personalized Eye Care | Stories in Life Sciences]]>What if doctors could predict how a patient will respond to treatment before giving it?

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Manuel Opitz, CEO and Co-founder of Deep Eye Medical, to explore how predictive AI is shifting ophthalmology from reactive treatment to personalized, data-driven care.

In ophthalmology today, the standard approach is trial and error. Treat, wait six to eight weeks, image again, then adjust. One in three patients drops out of treatment every year. When they stop coming, they go blind. Manuel's team built the first predictive AI approved in ophthalmology, a technology that predicts treatment response before the next injection and helps doctors keep patients engaged in their care.

We cover:

  • Why one in three ophthalmology patients drop out of treatment and what happens when they do
  • How Deep Eye Medical's predictive AI shifts care from "treat and extend" to "predict and treat"
  • Why 15 years of drug development has not improved treatment efficacy in ophthalmology
  • The regulatory path to becoming the first approved predictive AI in ophthalmology
  • What Manuel calls "the dark side" of commercialization and what founders should expect
  • The journey from engineer to CEO in a highly regulated healthcare AI environment
  • What personalized, predictive medicine looks like in clinical practice today

Who this is for: founders, clinicians, investors, and researchers in healthcare AI, ophthalmology, medical devices, and digital health who want to understand what predictive medicine looks like in practice.

Guest: 

Manuel Opitz, CEO and Co-founder, Deep Eye Medical 

https://deepeye-medical.com 

https://www.linkedin.com/in/manuelopitz 

https://www.linkedin.com/company/deepeye

Host:

Christopher Wilson, Founder, MedAxis AI www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>fe11ea05-5b48-4a5a-b982-43c83fd4e16eFri, 27 Mar 2026 11:47:19 GMT<p>What if doctors could predict how a patient will respond to treatment before giving it? </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Manuel Opitz, CEO and Co-founder of Deep Eye Medical, to explore how predictive AI is shifting ophthalmology from reactive treatment to personalized, data-driven care.</p><p></p><p>In ophthalmology today, the standard approach is trial and error. Treat, wait six to eight weeks, image again, then adjust. One in three patients drops out of treatment every year. When they stop coming, they go blind. Manuel's team built the first predictive AI approved in ophthalmology, a technology that predicts treatment response before the next injection and helps doctors keep patients engaged in their care.</p><p></p><p>We cover:</p><ul><li>Why one in three ophthalmology patients drop out of treatment and what happens when they do</li><li>How Deep Eye Medical's predictive AI shifts care from "treat and extend" to "predict and treat"</li><li>Why 15 years of drug development has not improved treatment efficacy in ophthalmology</li><li>The regulatory path to becoming the first approved predictive AI in ophthalmology</li><li>What Manuel calls "the dark side" of commercialization and what founders should expect</li><li>The journey from engineer to CEO in a highly regulated healthcare AI environment</li><li>What personalized, predictive medicine looks like in clinical practice today<p></p></li></ul><p>Who this is for: founders, clinicians, investors, and researchers in healthcare AI, ophthalmology, medical devices, and digital health who want to understand what predictive medicine looks like in practice.</p><p></p><p>Guest: </p><p>Manuel Opitz, CEO and Co-founder, Deep Eye Medical<a rel="noopener noreferrer nofollow" href="https://deepeye-medical.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://deepeye-medical.com" target="_blank">https://deepeye-medical.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/manuelopitz" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/manuelopitz" target="_blank">https://www.linkedin.com/in/manuelopitz</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/deepeye" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/deepeye" target="_blank">https://www.linkedin.com/company/deepeye</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI <a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.<br /></p>no00:46:48115Manuel Opitz: Predictive AI in Ophthalmology and Personalized Eye Care | Stories in Life Sciencesfull<![CDATA[Shem Lachhman Provisional Patents and IP Strategy for Biotech Founders Stories in Life Sciences]]>More foreign inventors are filing U.S. patents than Americans. The system built to protect innovation has become increasingly difficult for the founders and researchers it was designed to serve.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Shem Lachhman, Managing Partner and Co-Founder of Menlo Park Patents, to break down what founders actually need to know about protecting their IP.

Shem started as an electrical engineer building medical devices. After navigating expensive patent fees across multiple startups, he built Menlo Park Patents to make IP protection accessible at a fraction of traditional costs. His background spans tech transfer offices, medical device startups, and patent strategy, giving him a grounded perspective on where the system works and where it fails founders.

We cover:

  • Why the U.S. first-to-file system gives foreign competitors a structural advantage
  • What a provisional patent is and why it is every founder's first move
  • How academics and corporate employees can navigate IP ownership and invention rights
  • The risk of using AI tools like ChatGPT for patents and what the USPTO says about AI inventors
  • How Menlo Park Patents helps founders protect IP at a fraction of traditional costs
  • Lessons from building medical device startups and working with tech transfer offices
  • What first-time founders, researchers, and employee inventors need to know about IP strategy

Who this is for: biotech and medtech founders, academic researchers, and early-stage inventors who want to understand how to protect their IP without overcomplicating the process.

Guest: 

Shem Lachhman

Managing Partner and Co-Founder, Menlo Park Patents

https://menloparkpatents.com

https://www.linkedin.com/in/shemlachhman

https://www.linkedin.com/company/mppatents

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org
https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>52e24603-2b22-4006-8892-3f56b551bab7Fri, 27 Mar 2026 11:35:24 GMT<p>More foreign inventors are filing U.S. patents than Americans. The system built to protect innovation has become increasingly difficult for the founders and researchers it was designed to serve.</p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Shem Lachhman, Managing Partner and Co-Founder of Menlo Park Patents, to break down what founders actually need to know about protecting their IP.</p><p></p><p>Shem started as an electrical engineer building medical devices. After navigating expensive patent fees across multiple startups, he built Menlo Park Patents to make IP protection accessible at a fraction of traditional costs. His background spans tech transfer offices, medical device startups, and patent strategy, giving him a grounded perspective on where the system works and where it fails founders.</p><p></p><p>We cover:</p><ul><li>Why the U.S. first-to-file system gives foreign competitors a structural advantage</li><li>What a provisional patent is and why it is every founder's first move</li><li>How academics and corporate employees can navigate IP ownership and invention rights</li><li>The risk of using AI tools like ChatGPT for patents and what the USPTO says about AI inventors</li><li>How Menlo Park Patents helps founders protect IP at a fraction of traditional costs</li><li>Lessons from building medical device startups and working with tech transfer offices</li><li>What first-time founders, researchers, and employee inventors need to know about IP strategy<p></p></li></ul><p>Who this is for: biotech and medtech founders, academic researchers, and early-stage inventors who want to understand how to protect their IP without overcomplicating the process.</p><p></p><p>Guest: </p><p>Shem Lachhman</p><p>Managing Partner and Co-Founder, Menlo Park Patents</p><p><a rel="noopener noreferrer nofollow" href="https://menloparkpatents.com" target="_blank">https://menloparkpatents.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/shemlachhman" target="_blank">https://www.linkedin.com/in/shemlachhman</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/mppatents" target="_blank">https://www.linkedin.com/company/mppatents</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="www.medaxisai.org" target="_blank">www.medaxisai.org</a><br /><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:41:56114Shem Lachhman Provisional Patents and IP Strategy for Biotech Founders Stories in Life Sciencesfull<![CDATA[Dr. Vicky Ahuja: 3D-Printed Magnesium Implants That Bioresolve | Stories in Life Sciences]]>What if the implant that fixes your bone could disappear once you've healed? 

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Vicky Ahuja, CEO of OsseoLabs, to explore how 3D-printed magnesium implants are changing what patients and surgeons can expect from bone repair.

Unlike titanium implants that remain in the body permanently, OsseoLabs' magnesium plates do their job and then bioresolve, eliminating the need for a second surgery. Dr. Ahuja is also using AI to dramatically accelerate implant design, reducing a process that once took 40 hours to under one hour, making custom implants faster and more accessible for patients who need them.

We cover:

  • Why magnesium implants bioresolve inside the body and what that means for patients
  • How OsseoLabs' 3D-printed magnesium plates eliminate the need for second surgery
  • How AI reduced implant design time from 40 hours to under one hour
  • The strategy behind building clinical trust with titanium before introducing magnesium
  • The regulatory and commercial path for bioresolvable implant technology
  • Dr. Ahuja's journey to founding OsseoLabs and building a next-generation implant platform
  • The future of patient-specific, bioresolvable implants in bone and orthopedic surgery

Who this is for: surgeons, MedTech founders, investors, and researchers in orthopedics, biomaterials, AI in healthcare, and medical device innovation who want to understand where bioresolvable implant technology is headed.

Guest: 

Dr. Vicky Ahuja, CEO, OsseoLabs

https://www.osseolabs.com

https://www.linkedin.com/company/osseolabs 

https://www.linkedin.com/in/vikramahuja

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>517eb679-d8a2-4a89-b935-830136adf322Fri, 27 Mar 2026 11:31:16 GMT<p>What if the implant that fixes your bone could disappear once you've healed? </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Vicky Ahuja, CEO of OsseoLabs, to explore how 3D-printed magnesium implants are changing what patients and surgeons can expect from bone repair.</p><p></p><p>Unlike titanium implants that remain in the body permanently, OsseoLabs' magnesium plates do their job and then bioresolve, eliminating the need for a second surgery. Dr. Ahuja is also using AI to dramatically accelerate implant design, reducing a process that once took 40 hours to under one hour, making custom implants faster and more accessible for patients who need them.</p><p></p><p>We cover:</p><ul><li>Why magnesium implants bioresolve inside the body and what that means for patients</li><li>How OsseoLabs' 3D-printed magnesium plates eliminate the need for second surgery</li><li>How AI reduced implant design time from 40 hours to under one hour</li><li>The strategy behind building clinical trust with titanium before introducing magnesium</li><li>The regulatory and commercial path for bioresolvable implant technology</li><li>Dr. Ahuja's journey to founding OsseoLabs and building a next-generation implant platform</li><li>The future of patient-specific, bioresolvable implants in bone and orthopedic surgery<p></p></li></ul><p>Who this is for: surgeons, MedTech founders, investors, and researchers in orthopedics, biomaterials, AI in healthcare, and medical device innovation who want to understand where bioresolvable implant technology is headed.</p><p></p><p>Guest: </p><p>Dr. Vicky Ahuja, CEO, OsseoLabs</p><p><a rel="noopener noreferrer nofollow" href="https://www.osseolabs.com" target="_blank">https://www.osseolabs.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/osseolabs" target="_blank">https://www.linkedin.com/company/osseolabs</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/vikramahuja" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/vikramahuja" target="_blank">https://www.linkedin.com/in/vikramahuja</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.<br /></p>no00:35:31113Dr. Vicky Ahuja: 3D-Printed Magnesium Implants That Bioresolve | Stories in Life Sciencesfull<![CDATA[Talal Ali Ahmad AI-Powered Wound Monitoring and Remote Patient Care Stories in Life Sciences]]>A surgeon told him: "If you had sent me a good picture, I could have saved you the trip." That seven-hour ER wait with his son became the origin story for Predictive Healthcare.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Talal Ali Ahmad, Founder and CEO of Predictive Healthcare, to explore how AI is closing the visibility gap between hospital discharge and post-surgical recovery.

Talal's background in communications engineering shaped his approach to a problem most healthcare systems haven't solved: patients go home after surgery with no reliable way for clinicians to monitor wound healing remotely. His platform, My Health Pal, guides patients to capture clinical-grade wound images and flags complications before they escalate, reducing unnecessary ER visits and giving surgeons the visual data they need to make remote decisions confidently.

We cover:

  • Why post-surgical patients fall into a visibility gap once they leave the hospital
  • How My Health Pal guides patients to capture clinical-grade wound images remotely
  • How inverse engineering in image capture unlocks reliable wound monitoring at home
  • What 18-month hospital sales cycles teach founders about navigating healthcare procurement
  • Why doctors expect AI to be 100% accurate from day one and how to reset those expectations
  • Talal's journey from communications engineering to MedTech entrepreneurship
  • The commercial strategy behind building an AI platform for clinical remote care

Who this is for: founders, clinicians, investors, and researchers in MedTech, digital health, remote patient monitoring, and AI in healthcare who want to understand how AI is changing post-surgical care.

Guest: 

Talal Ali Ahmad 

Founder and CEO, Predictive Healthcare 

https://predictivehealthcare.ai 

https://www.linkedin.com/in/talalaliahmad

https://www.linkedin.com/company/predictivehealthcareai

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>e68f53a2-3cd8-4156-90d2-83df900b4067Fri, 27 Mar 2026 11:27:34 GMT<p>A surgeon told him: "If you had sent me a good picture, I could have saved you the trip." That seven-hour ER wait with his son became the origin story for Predictive Healthcare. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Talal Ali Ahmad, Founder and CEO of Predictive Healthcare, to explore how AI is closing the visibility gap between hospital discharge and post-surgical recovery.</p><p></p><p>Talal's background in communications engineering shaped his approach to a problem most healthcare systems haven't solved: patients go home after surgery with no reliable way for clinicians to monitor wound healing remotely. His platform, My Health Pal, guides patients to capture clinical-grade wound images and flags complications before they escalate, reducing unnecessary ER visits and giving surgeons the visual data they need to make remote decisions confidently.</p><p></p><p>We cover:</p><ul><li>Why post-surgical patients fall into a visibility gap once they leave the hospital</li><li>How My Health Pal guides patients to capture clinical-grade wound images remotely</li><li>How inverse engineering in image capture unlocks reliable wound monitoring at home</li><li>What 18-month hospital sales cycles teach founders about navigating healthcare procurement</li><li>Why doctors expect AI to be 100% accurate from day one and how to reset those expectations</li><li>Talal's journey from communications engineering to MedTech entrepreneurship</li><li>The commercial strategy behind building an AI platform for clinical remote care<p></p></li></ul><p>Who this is for: founders, clinicians, investors, and researchers in MedTech, digital health, remote patient monitoring, and AI in healthcare who want to understand how AI is changing post-surgical care.</p><p></p><p>Guest: </p><p>Talal Ali Ahmad </p><p>Founder and CEO, Predictive Healthcare<a rel="noopener noreferrer nofollow" href="https://predictivehealthcare.ai" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://predictivehealthcare.ai" target="_blank">https://predictivehealthcare.ai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/talalaliahmad" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/talalaliahmad" target="_blank">https://www.linkedin.com/in/talalaliahmad</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/predictivehealthcareai" target="_blank">https://www.linkedin.com/company/predictivehealthcareai</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:32:59112Talal Ali Ahmad AI-Powered Wound Monitoring and Remote Patient Care Stories in Life Sciencesfull<![CDATA[ Suleen Raad Human-Relevant Models and AI in Drug Discovery Stories in Life Sciences]]>We have made enormous progress in drug discovery. Yet most therapies still fail when they reach humans.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Suleen Raad, Co-founder and Chief Operating Officer of Telescope Therapeutics, to explore why traditional animal models continue to fall short and how human-relevant biology paired with AI could change the odds.

Suleen's transition from academic research into biotech entrepreneurship is grounded in a clear conviction: the future of drug discovery depends on modeling disease in systems that actually reflect human biology. Her work brings together stem cells, organoids, and biosensors to study disease progression earlier and more accurately.

Telescope Therapeutics is applying this approach to cardiac fibrosis, a major and often overlooked driver of heart failure with no targeted therapies available today. The company uses human stem-cell models combined with AI-driven virtual screening to identify potential treatments faster, cheaper, and with greater translational relevance. This conversation is about fixing the foundations of drug discovery so science has a better chance of reaching patients.

We cover:

  • Why traditional animal models continue to fall short in drug discovery
  • How human-relevant models using stem cells, organoids, and biosensors improve translational success
  • Telescope Therapeutics' approach to cardiac fibrosis, a major unmet need in heart failure
  • How AI-driven virtual screening accelerates and focuses drug candidate identification
  • Why better models matter more than more data in early-stage research
  • Suleen's transition from academic research to biotech entrepreneurship
  • What translational success requires beyond biology alone

Who this is for: founders, researchers, and investors in drug discovery, cardiovascular disease, AI in healthcare, and life sciences who want to understand how human-relevant models are changing the path from lab to patient.

Guest:

Suleen Raad, PhD 

Co-founder and Chief Operating Officer

Telescope Therapeutics

https://www.telescopetherapeutics.com https://www.linkedin.com/company/telescopetherapeutics https://www.linkedin.com/in/suleenraad

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>47cc8487-e30e-4375-9226-ac28dead19bbFri, 27 Mar 2026 04:05:53 GMT<p>We have made enormous progress in drug discovery. Yet most therapies still fail when they reach humans.</p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Suleen Raad, Co-founder and Chief Operating Officer of Telescope Therapeutics, to explore why traditional animal models continue to fall short and how human-relevant biology paired with AI could change the odds.</p><p></p><p>Suleen's transition from academic research into biotech entrepreneurship is grounded in a clear conviction: the future of drug discovery depends on modeling disease in systems that actually reflect human biology. Her work brings together stem cells, organoids, and biosensors to study disease progression earlier and more accurately.</p><p></p><p>Telescope Therapeutics is applying this approach to cardiac fibrosis, a major and often overlooked driver of heart failure with no targeted therapies available today. The company uses human stem-cell models combined with AI-driven virtual screening to identify potential treatments faster, cheaper, and with greater translational relevance. This conversation is about fixing the foundations of drug discovery so science has a better chance of reaching patients.</p><p></p><p>We cover:</p><ul><li>Why traditional animal models continue to fall short in drug discovery</li><li>How human-relevant models using stem cells, organoids, and biosensors improve translational success</li><li>Telescope Therapeutics' approach to cardiac fibrosis, a major unmet need in heart failure</li><li>How AI-driven virtual screening accelerates and focuses drug candidate identification</li><li>Why better models matter more than more data in early-stage research</li><li>Suleen's transition from academic research to biotech entrepreneurship</li><li>What translational success requires beyond biology alone<p></p></li></ul><p>Who this is for: founders, researchers, and investors in drug discovery, cardiovascular disease, AI in healthcare, and life sciences who want to understand how human-relevant models are changing the path from lab to patient.</p><p></p><p>Guest:</p><p>Suleen Raad, PhD </p><p>Co-founder and Chief Operating Officer</p><p>Telescope Therapeutics</p><p><a rel="noopener noreferrer nofollow" href="https://www.telescopetherapeutics.com" target="_blank">https://www.telescopetherapeutics.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/telescopetherapeutics" target="_blank"> https://www.linkedin.com/company/telescopetherapeutics</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/suleenraad" target="_blank"> https://www.linkedin.com/in/suleenraad</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:37:27111 Suleen Raad Human-Relevant Models and AI in Drug Discovery Stories in Life Sciencesfull<![CDATA[Jessika Valero Gonzalez: Antibody Engineering and Early Cancer Detection | Stories in Life Sciences]]>Many promising cancer proteins are nearly impossible to detect. Not because of biology, but because of engineering.

Christopher Wilson sits down with Jessika Valero Gonzalez, Chief Research Officer at BioClonal, to explore how advanced antibody engineering is unlocking targets that traditional methods and animal models miss.

Jessika's path runs from chemistry and protein science into biotech leadership, driven by a clear mission to translate science into patient impact. At BioClonal, she is helping build a platform focused on monoclonal antibodies for challenging cancer targets, using inverse engineering and super immunogens to overcome the limitations of conventional approaches.

In this episode of Stories in Life Sciences, we cover:

  • Why many cancer detection failures are engineering problems, not biology problems
  • How inverse engineering and super immunogens unlock targets animal models miss
  • BioClonal's platform approach to monoclonal antibody development for challenging targets
  • Commercialization strategy: platform partnerships versus internal pipeline development
  • Why early market feedback is critical in long biotech development cycles
  • What it takes to move deep biotech innovation from lab to market
  • Jessika's journey from chemistry and protein science to biotech leadership

Who this is for: researchers, founders, and investors in oncology, antibody engineering, biotech diagnostics, and life sciences commercialization who want to understand where cancer detection technology is headed.

Guest: 

Jessika Valero Gonzalez

Chief Research Officer, BioClonal 

https://bioclonal.es

https://www.linkedin.com/company/bioclonalhttps://www.linkedin.com/in/jessika-valero

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>3417536e-98d9-4f50-a00e-ca3a3fe75d47Fri, 27 Mar 2026 03:58:24 GMT<p>Many promising cancer proteins are nearly impossible to detect. Not because of biology, but because of engineering. </p><p></p><p>Christopher Wilson sits down with Jessika Valero Gonzalez, Chief Research Officer at BioClonal, to explore how advanced antibody engineering is unlocking targets that traditional methods and animal models miss.</p><p></p><p>Jessika's path runs from chemistry and protein science into biotech leadership, driven by a clear mission to translate science into patient impact. At BioClonal, she is helping build a platform focused on monoclonal antibodies for challenging cancer targets, using inverse engineering and super immunogens to overcome the limitations of conventional approaches.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>Why many cancer detection failures are engineering problems, not biology problems</li><li>How inverse engineering and super immunogens unlock targets animal models miss</li><li>BioClonal's platform approach to monoclonal antibody development for challenging targets</li><li>Commercialization strategy: platform partnerships versus internal pipeline development</li><li>Why early market feedback is critical in long biotech development cycles</li><li>What it takes to move deep biotech innovation from lab to market</li><li>Jessika's journey from chemistry and protein science to biotech leadership<p></p></li></ul><p>Who this is for: researchers, founders, and investors in oncology, antibody engineering, biotech diagnostics, and life sciences commercialization who want to understand where cancer detection technology is headed.</p><p></p><p>Guest: </p><p>Jessika Valero Gonzalez</p><p>Chief Research Officer, BioClonal<a rel="noopener noreferrer nofollow" href="https://bioclonal.es" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://bioclonal.es" target="_blank">https://bioclonal.es</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/bioclonalhttps://www.linkedin.com/in/jessika-valero" target="_blank">https://www.linkedin.com/company/bioclonalhttps://www.linkedin.com/in/jessika-valero</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:39:48110Jessika Valero Gonzalez: Antibody Engineering and Early Cancer Detection | Stories in Life Sciencesfull<![CDATA[Nina Granucci Turning Food Waste into Functional Ingredients Stories in Life Sciences]]>Most food byproducts are thrown away or downcycled, taking their nutritional value with them.

Christopher Wilson sits down with Nina Granucci, Co-founder and President of Green Spot Technologies, to explore how solid-state fermentation is transforming food waste into scalable, high-value functional ingredients.

Green Spot Technologies works with fruit, vegetable, legume, and cereal side streams, turning what manufacturers discard into ingredients that preserve nutrition and perform at commercial scale. Nina brings a grounded perspective on what it takes to move deep science into a real business, from listening to customers rather than selling technology, to raising capital and building the right team in today's venture landscape.

In this episode of Stories in Life Sciences, we cover:

  • How solid-state fermentation transforms food byproducts into high-value functional ingredients
  • Why food waste contains some of the most nutritious parts of our food system
  • Green Spot Technologies' approach to upcycling fruit, vegetable, legume, and cereal side streams
  • Why sustainability only works when the product also performs commercially
  • How scientists must shift from technology-first to customer-first thinking to scale
  • Creative funding strategies for deep tech companies in today's venture landscape
  • The role of mentorship and networks at every stage of growth

Who this is for: founders, investors, and researchers in food tech, sustainable ingredients, fermentation science, and life sciences commercialization who want to understand how food waste becomes a scalable business.

Guest: 

Nina Granucci

Co-founder and President, Green Spot Technologies 

https://greenspot-tech.com/en

https://www.linkedin.com/company/greenspot-tech

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>258e7d5a-4f75-43c4-8c78-d6f8e8c8a75fFri, 27 Mar 2026 03:49:03 GMT<p>Most food byproducts are thrown away or downcycled, taking their nutritional value with them. </p><p></p><p>Christopher Wilson sits down with Nina Granucci, Co-founder and President of Green Spot Technologies, to explore how solid-state fermentation is transforming food waste into scalable, high-value functional ingredients.</p><p></p><p>Green Spot Technologies works with fruit, vegetable, legume, and cereal side streams, turning what manufacturers discard into ingredients that preserve nutrition and perform at commercial scale. Nina brings a grounded perspective on what it takes to move deep science into a real business, from listening to customers rather than selling technology, to raising capital and building the right team in today's venture landscape.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>How solid-state fermentation transforms food byproducts into high-value functional ingredients</li><li>Why food waste contains some of the most nutritious parts of our food system</li><li>Green Spot Technologies' approach to upcycling fruit, vegetable, legume, and cereal side streams</li><li>Why sustainability only works when the product also performs commercially</li><li>How scientists must shift from technology-first to customer-first thinking to scale</li><li>Creative funding strategies for deep tech companies in today's venture landscape</li><li>The role of mentorship and networks at every stage of growth<p></p></li></ul><p>Who this is for: founders, investors, and researchers in food tech, sustainable ingredients, fermentation science, and life sciences commercialization who want to understand how food waste becomes a scalable business.</p><p></p><p>Guest: </p><p>Nina Granucci</p><p>Co-founder and President, Green Spot Technologies<a rel="noopener noreferrer nofollow" href="https://greenspot-tech.com/en" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://greenspot-tech.com/en" target="_blank">https://greenspot-tech.com/en</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/greenspot-tech" target="_blank">https://www.linkedin.com/company/greenspot-tech</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:36:1719Nina Granucci Turning Food Waste into Functional Ingredients Stories in Life Sciencesfull<![CDATA[Karl Schmieder Biotech Storytelling, Strategy, and Commercialization Stories in Life Sciences]]>Most biotech founders are deeply fluent in their science. Fewer are fluent in the story that moves their market. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Karl Schmieder, Founder of MessagingLab and co-host of the Grow Everything podcast, to explore how strategic communication and narrative shape the path from discovery to commercialization.

Karl's background spans biochemistry and creative writing, a combination that led him to build a practice helping biotech innovators translate complex science into messaging that drives adoption. He works with founders at every stage of the product lifecycle to sharpen strategy, clarify value, and build narratives that accelerate market entry.

In this episode of Stories in Life Sciences, we cover:

  • Why biotech founders struggle to communicate their value to non-scientific audiences
  • How to tailor messaging for each audience across the product lifecycle
  • Why niche focus and ecosystem thinking are essential for biotech commercialization
  • The role of AI as a strategic collaborator in research, marketing, and go-to-market planning
  • How Karl's path from biochemistry to creative writing shaped his approach to biotech strategy
  • The most common communication pitfalls as companies move from discovery to market
  • Why the fastest-growing biotech companies invest in strategic storytelling early

Who this is for: biotech and medtech founders, commercialization leads, and life sciences marketers who want to understand how strategic communication drives market adoption.

Guest: 

Karl Schmieder

CEO and Founder, MessagingLab 

https://www.messaginglab.com 

https://www.linkedin.com/company/messaginglab


Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.


]]>39b7fa8a-093b-49a9-8f26-6592458ddb63Fri, 27 Mar 2026 03:34:11 GMT<p>Most biotech founders are deeply fluent in their science. Fewer are fluent in the story that moves their market. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Karl Schmieder, Founder of MessagingLab and co-host of the Grow Everything podcast, to explore how strategic communication and narrative shape the path from discovery to commercialization.</p><p></p><p>Karl's background spans biochemistry and creative writing, a combination that led him to build a practice helping biotech innovators translate complex science into messaging that drives adoption. He works with founders at every stage of the product lifecycle to sharpen strategy, clarify value, and build narratives that accelerate market entry.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>Why biotech founders struggle to communicate their value to non-scientific audiences</li><li>How to tailor messaging for each audience across the product lifecycle</li><li>Why niche focus and ecosystem thinking are essential for biotech commercialization</li><li>The role of AI as a strategic collaborator in research, marketing, and go-to-market planning</li><li>How Karl's path from biochemistry to creative writing shaped his approach to biotech strategy</li><li>The most common communication pitfalls as companies move from discovery to market</li><li>Why the fastest-growing biotech companies invest in strategic storytelling early<p></p></li></ul><p>Who this is for: biotech and medtech founders, commercialization leads, and life sciences marketers who want to understand how strategic communication drives market adoption.</p><p></p><p>Guest: </p><p>Karl Schmieder</p><p>CEO and Founder, MessagingLab<a rel="noopener noreferrer nofollow" href="https://www.messaginglab.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.messaginglab.com" target="_blank">https://www.messaginglab.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/messaginglab" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/messaginglab" target="_blank">https://www.linkedin.com/company/messaginglab</a></p><p><br />Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p><br /></p>no00:39:3618Karl Schmieder Biotech Storytelling, Strategy, and Commercialization Stories in Life Sciencesfull<![CDATA[Dr. Jennifer Altomonte Smarter Cancer Therapies with Fusix Biotech Stories in Life Sciences]]>Most cancer therapies target tumors from a single angle. When tumors adapt and escape, treatment stops working.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Jennifer Altomonte, molecular biologist and founder of Fusix Biotech, to explore a different approach built on engineered viruses that attack tumors from multiple directions at once.

Dr. Altomonte shares her journey from New York to Munich, decades in virus engineering, and the moment she realized her lab had developed something with the potential to change how cancer is treated. Fusix Biotech's therapy kills tumor cells directly, delivers immune-boosting genes, and activates the patient's immune system to continue fighting long after the drug is gone.

In this episode of Stories in Life Sciences, we cover:

  • How engineered oncolytic viruses attack tumors from multiple angles to overcome resistance
  • The science behind Fusix Biotech's approach to cancer therapy
  • Why hitting tumors with multiple mechanisms reduces the risk of immune escape
  • The role of AI in identifying biomarkers and guiding cancer therapy development
  • Dr. Altomonte's journey from academic virus engineering to biotech entrepreneurship
  • The transition from academia to founding a biotech company and what it requires
  • Building conviction and networks in a field where failure is common

Who this is for: oncology researchers, biotech founders, clinicians, and investors in cancer therapy, immunotherapy, and life sciences innovation who want to understand where engineered virus platforms are headed.

Guest: 

Dr. Jennifer Altomonte

Managing Director and CSO, Fusix Biotech 

www.fusixbiotech.de 

https://www.linkedin.com/company/fusix-biotech

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>dbf7eaf5-69c7-4cd0-83b2-49c9e46a02dcFri, 27 Mar 2026 03:21:50 GMT<p>Most cancer therapies target tumors from a single angle. When tumors adapt and escape, treatment stops working. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Jennifer Altomonte, molecular biologist and founder of Fusix Biotech, to explore a different approach built on engineered viruses that attack tumors from multiple directions at once.</p><p></p><p>Dr. Altomonte shares her journey from New York to Munich, decades in virus engineering, and the moment she realized her lab had developed something with the potential to change how cancer is treated. Fusix Biotech's therapy kills tumor cells directly, delivers immune-boosting genes, and activates the patient's immune system to continue fighting long after the drug is gone.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>How engineered oncolytic viruses attack tumors from multiple angles to overcome resistance</li><li>The science behind Fusix Biotech's approach to cancer therapy</li><li>Why hitting tumors with multiple mechanisms reduces the risk of immune escape</li><li>The role of AI in identifying biomarkers and guiding cancer therapy development</li><li>Dr. Altomonte's journey from academic virus engineering to biotech entrepreneurship</li><li>The transition from academia to founding a biotech company and what it requires</li><li>Building conviction and networks in a field where failure is common<p></p></li></ul><p>Who this is for: oncology researchers, biotech founders, clinicians, and investors in cancer therapy, immunotherapy, and life sciences innovation who want to understand where engineered virus platforms are headed.</p><p></p><p>Guest: </p><p>Dr. Jennifer Altomonte</p><p>Managing Director and CSO, Fusix Biotech<a rel="noopener noreferrer nofollow" href="http://www.fusixbiotech.de" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="http://www.fusixbiotech.de" target="_blank">www.fusixbiotech.de</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/fusix-biotech" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/fusix-biotech" target="_blank">https://www.linkedin.com/company/fusix-biotech</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><h2><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></h2><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p><p></p>no00:34:5517Dr. Jennifer Altomonte Smarter Cancer Therapies with Fusix Biotech Stories in Life Sciencesfull<![CDATA[Dr. Sonia Trigueros Nanotechnology and AI in Early Diagnostics Stories in Life Sciences]]>"You always realize you are already late. By the time that you apply the therapy, it's too late."

What if early diagnostics became the new standard of care? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Sonia Trigueros, Founder of NIVD and former Co-Director of the Nanotechnology Program at Oxford, to explore how nanotechnology, quantum materials, and AI are opening an entirely new frontier in healthcare.

Dr. Trigueros is working to detect sepsis, cancer, autoimmune diseases, and infections before a single symptom appears, using diagnostic tools that require no electricity and can reach underserved communities globally. Her work sits at the intersection of physics, biology, medicine, and commercialization, and her vision is to make ultra-early detection accessible at the point of care worldwide.

In this episode of Stories in Life Sciences, we cover:

  • How nanotechnology and quantum materials enable ultra-early disease detection
  • Why early diagnosis is the missing link in effective therapies for cancer and sepsis
  • How AI can correlate clinical, molecular, and unknown datasets to reveal hidden biological relationships
  • NIVD's vision for electricity-free, point-of-care diagnostics in underserved communities
  • Dr. Trigueros' journey from Oxford nanotechnology research to founding NIVD
  • Building a multidisciplinary team across physics, biology, medicine, and commercialization
  • The future of accessible diagnostics and global health equity

Who this is for: founders, clinicians, researchers, and investors in diagnostics, nanotechnology, AI in healthcare, global health, and life sciences who want to understand where early detection technology is headed.

Guest: 

Dr. Sonia Trigueros, Founder and Director, NIVD

www.nivd.world 

https://www.linkedin.com/company/nivdworld

Host:

Christopher Wilson, Founder, MedAxis AI www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>8e622ac7-62ec-44fd-99d9-92498e328de6Thu, 26 Mar 2026 15:12:54 GMT<p>"You always realize you are already late. By the time that you apply the therapy, it's too late."</p><p></p><p>What if early diagnostics became the new standard of care? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Sonia Trigueros, Founder of NIVD and former Co-Director of the Nanotechnology Program at Oxford, to explore how nanotechnology, quantum materials, and AI are opening an entirely new frontier in healthcare.</p><p></p><p>Dr. Trigueros is working to detect sepsis, cancer, autoimmune diseases, and infections before a single symptom appears, using diagnostic tools that require no electricity and can reach underserved communities globally. Her work sits at the intersection of physics, biology, medicine, and commercialization, and her vision is to make ultra-early detection accessible at the point of care worldwide.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>How nanotechnology and quantum materials enable ultra-early disease detection</li><li>Why early diagnosis is the missing link in effective therapies for cancer and sepsis</li><li>How AI can correlate clinical, molecular, and unknown datasets to reveal hidden biological relationships</li><li>NIVD's vision for electricity-free, point-of-care diagnostics in underserved communities</li><li>Dr. Trigueros' journey from Oxford nanotechnology research to founding NIVD</li><li>Building a multidisciplinary team across physics, biology, medicine, and commercialization</li><li>The future of accessible diagnostics and global health equity<p></p></li></ul><p>Who this is for: founders, clinicians, researchers, and investors in diagnostics, nanotechnology, AI in healthcare, global health, and life sciences who want to understand where early detection technology is headed.</p><p></p><p>Guest: </p><p>Dr. Sonia Trigueros, Founder and Director, NIVD</p><p><a rel="noopener noreferrer nofollow" href="http://www.nivd.world" target="_blank">www.nivd.world</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/nivdworld" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/nivdworld" target="_blank">https://www.linkedin.com/company/nivdworld</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI <a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:39:0016Dr. Sonia Trigueros Nanotechnology and AI in Early Diagnostics Stories in Life Sciencesfull<![CDATA[Vanloan Nguyen: Launching 100 Biotech Startups with AI and Drug Discovery | Stories in Life Sciences]]>What does it take to turn a scientist into a successful biotech founder? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vanloan Nguyen, Founder and Executive Director of Berkeley Pharma Tech, to explore the realities of building and scaling life sciences startups from the ground up.

Vanloan has navigated the full arc from bench scientist to angel investor to founder, and now leads an ambitious program to incubate and launch 100 biotech startups in ten years. She brings a perspective that combines scientific rigor with the strategic pragmatism of an investor, including candid lessons from her own experience of startup failure alongside a serial entrepreneur.

In this episode of Stories in Life Sciences, we cover:

  • Berkeley Pharma Tech's mission to launch 100 biotech startups in ten years
  • How AI is automating and accelerating 800-page FDA submissions
  • Why data quality is the new gold standard for AI in drug discovery
  • The role of CRISPR and genetic editing coming out of UC Berkeley
  • What causes startups to fail even with strong teams and experienced founders
  • Why in-person relationship building is non-negotiable in biotech investing
  • The transition from pre-med scientist to angel investor and biotech founder

Who this is for: early-stage founders, life sciences investors, and researchers in biotech, drug discovery, AI in healthcare, and pharmaceutical R&D who want to understand what it takes to build a commercially viable biotech company.

Guest:

Vanloan Nguyen, Founder and Executive Director

Berkeley Pharma Tech President and Director

Berkeley Pharma Tech Foundation www.berkeleypharmatech.com

https://www.linkedin.com/company/berkeleypharmatechfosteringinnovations

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org 

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>f43825eb-1a97-4f4c-b295-ebc7526685e3Thu, 26 Mar 2026 14:43:18 GMT<p>What does it take to turn a scientist into a successful biotech founder? In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Vanloan Nguyen, Founder and Executive Director of Berkeley Pharma Tech, to explore the realities of building and scaling life sciences startups from the ground up.</p><p>Vanloan has navigated the full arc from bench scientist to angel investor to founder, and now leads an ambitious program to incubate and launch 100 biotech startups in ten years. She brings a perspective that combines scientific rigor with the strategic pragmatism of an investor, including candid lessons from her own experience of startup failure alongside a serial entrepreneur.</p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>Berkeley Pharma Tech's mission to launch 100 biotech startups in ten years</li><li>How AI is automating and accelerating 800-page FDA submissions</li><li>Why data quality is the new gold standard for AI in drug discovery</li><li>The role of CRISPR and genetic editing coming out of UC Berkeley</li><li>What causes startups to fail even with strong teams and experienced founders</li><li>Why in-person relationship building is non-negotiable in biotech investing</li><li>The transition from pre-med scientist to angel investor and biotech founder</li></ul><p>Who this is for: early-stage founders, life sciences investors, and researchers in biotech, drug discovery, AI in healthcare, and pharmaceutical R&amp;D who want to understand what it takes to build a commercially viable biotech company.</p><p></p><p>Guest:</p><p>Vanloan Nguyen, Founder and Executive Director</p><p>Berkeley Pharma Tech President and Director</p><p>Berkeley Pharma Tech Foundation <a rel="noopener noreferrer nofollow" href="http://www.berkeleypharmatech.com" target="_blank">www.berkeleypharmatech.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/berkeleypharmatechfosteringinnovations" target="_blank">https://www.linkedin.com/company/berkeleypharmatechfosteringinnovations</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><h2><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank"> </a></h2><h2><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></h2><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:24:3115Vanloan Nguyen: Launching 100 Biotech Startups with AI and Drug Discovery | Stories in Life Sciencesfull<![CDATA[Dr. Kim Kjøller: Precision Medicine and AI in Drug Development | Stories in Life Sciences]]>Drug development is being reshaped by AI, precision medicine, and a growing culture of collaboration across the life sciences. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Kim Kjøller, CEO of Union Therapeutics, to explore what that transformation looks like from inside a leading biotech company.

Dr. Kjøller draws on decades of experience in Big Pharma to discuss how Union Therapeutics is advancing therapies for chronic diseases, why Denmark's collaborative biotech ecosystem has become a global model for life sciences innovation, and what it takes to bring a European biotech into the U.S. healthcare market.

In this episode of Stories in Life Sciences, we cover:

  • How AI is accelerating data-driven drug discovery and development
  • Union Therapeutics' approach to advancing therapies for chronic diseases
  • Lessons from decades in Big Pharma applied to biotech innovation
  • Why Denmark's Life Science Cluster is a global model for collaboration
  • The challenges of entering the U.S. healthcare market as a European biotech
  • The growing role of precision medicine and prevention in patient care

Who this is for: founders, investors, clinicians, and researchers in biotech, pharma R&D, precision medicine, and life sciences who want to understand how collaboration and AI are changing drug development.

Guest: 

Dr. Kim Kjøller, CEO, Union Therapeutics 

www.uniontherapeutics.com

https://www.linkedin.com/company/uniontherapeutics

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>53b8e522-ea3a-4e56-8785-05e9c7c814fbThu, 26 Mar 2026 14:36:16 GMT<p>Drug development is being reshaped by AI, precision medicine, and a growing culture of collaboration across the life sciences. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Kim Kjøller, CEO of Union Therapeutics, to explore what that transformation looks like from inside a leading biotech company.</p><p></p><p>Dr. Kjøller draws on decades of experience in Big Pharma to discuss how Union Therapeutics is advancing therapies for chronic diseases, why Denmark's collaborative biotech ecosystem has become a global model for life sciences innovation, and what it takes to bring a European biotech into the U.S. healthcare market.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>How AI is accelerating data-driven drug discovery and development</li><li>Union Therapeutics' approach to advancing therapies for chronic diseases</li><li>Lessons from decades in Big Pharma applied to biotech innovation</li><li>Why Denmark's Life Science Cluster is a global model for collaboration</li><li>The challenges of entering the U.S. healthcare market as a European biotech</li><li>The growing role of precision medicine and prevention in patient care<p></p></li></ul><p>Who this is for: founders, investors, clinicians, and researchers in biotech, pharma R&amp;D, precision medicine, and life sciences who want to understand how collaboration and AI are changing drug development.</p><p></p><p>Guest: </p><p>Dr. Kim Kjøller, CEO, Union Therapeutics<a rel="noopener noreferrer nofollow" href="http://www.uniontherapeutics.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="http://www.uniontherapeutics.com" target="_blank">www.uniontherapeutics.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/uniontherapeutics" target="_blank">https://www.linkedin.com/company/uniontherapeutics</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p> <a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:32:1814Dr. Kim Kjøller: Precision Medicine and AI in Drug Development | Stories in Life Sciencesfull<![CDATA[Michael Schrader: How AI Is Changing Biotech Startups Stories in Life Sciences]]>Artificial intelligence is reshaping how biotech companies are built, funded, and scaled. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Schrader, Co-founder and former CEO of Vaxess Technologies, to explore what that shift means for the next generation of founders.

Michael's path from mechanical engineer to biotech entrepreneur spans mission-driven innovation, creative problem-solving, and the hard lessons of building a globally recognized vaccine delivery company. He brings a grounded perspective on what it actually takes to launch and grow a biotech startup in today's landscape.

In this episode of Stories in Life Sciences, we cover:

  • How AI is lowering barriers for new biotech founders in design, prototyping, and regulatory work
  • Lessons from building Vaxess Technologies, a globally recognized vaccine delivery company
  • The role of mission and perseverance in biotech entrepreneurship
  • How creative funding models and global thinking support biotech growth
  • Why collaboration and diversity drive better problem-solving in life sciences
  • What the next generation of AI-powered biotech startups looks like

Who this is for: founders, investors, and researchers in biotech, deep tech, AI in healthcare, and life sciences who want to understand how artificial intelligence is changing how companies are built.

Guest:

Michael Schrader

Co-founder and Former CEO, Vaxess Technologies https://www.linkedin.com/in/michaelschrader

Host:

Christopher Wilson

Found, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>6e54f330-be10-4e58-917c-90c68e7dd342Thu, 26 Mar 2026 14:13:06 GMT<p>Artificial intelligence is reshaping how biotech companies are built, funded, and scaled. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Michael Schrader, Co-founder and former CEO of Vaxess Technologies, to explore what that shift means for the next generation of founders.</p><p>Michael's path from mechanical engineer to biotech entrepreneur spans mission-driven innovation, creative problem-solving, and the hard lessons of building a globally recognized vaccine delivery company. He brings a grounded perspective on what it actually takes to launch and grow a biotech startup in today's landscape.</p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>How AI is lowering barriers for new biotech founders in design, prototyping, and regulatory work</li><li>Lessons from building Vaxess Technologies, a globally recognized vaccine delivery company</li><li>The role of mission and perseverance in biotech entrepreneurship</li><li>How creative funding models and global thinking support biotech growth</li><li>Why collaboration and diversity drive better problem-solving in life sciences</li><li>What the next generation of AI-powered biotech startups looks like</li></ul><p>Who this is for: founders, investors, and researchers in biotech, deep tech, AI in healthcare, and life sciences who want to understand how artificial intelligence is changing how companies are built.</p><p></p><p>Guest: </p><p>Michael Schrader</p><p>Co-founder and Former CEO, Vaxess Technologies <a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/michaelschrader" target="_blank">https://www.linkedin.com/in/michaelschrader</a></p><p></p><p>Host:</p><p>Christopher Wilson</p><p>Found, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:35:5713Michael Schrader: How AI Is Changing Biotech Startups Stories in Life Sciencesfull<![CDATA[Hera Biotech: Precision Diagnostics for Endometriosis and Women's Health | Stories in Life Sciences]]>For decades, women's health has been under-researched, underfunded, and underserved. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Somer Barburek, CEO and Co-founder of Hera Biotech, to explore how precision diagnostics and molecular innovation are starting to change that.

Somer's path to biotech founder ran through professional rodeo athletics and a firsthand understanding of how little the healthcare system was built around women's biology. At Hera Biotech, she's building a platform that uses molecular and machine-learning diagnostics to detect endometriosis earlier and more accurately, replacing invasive surgery with simple, office-based testing.

In this episode of Stories in Life Sciences, we cover:

  • Why women's health has been historically underfunded and what that means for patients today
  • How Hera Biotech is tackling endometriosis with molecular and AI-driven diagnostics
  • The shift from invasive surgical diagnosis to office-based precision testing
  • Somer's journey from professional rodeo athlete to biotech founder
  • The realities of biotech commercialization and scaling a women's health company
  • What a more equitable, data-driven future in medicine actually looks like

Who this is for: founders, clinicians, investors, and researchers in women's health, biotech diagnostics, medtech, and digital health who want to understand where precision medicine for women is headed.

Guest: 

Somer Barburek, CEO and Co-founder, Hera Biotech 

www.herabiotech.com 

https://www.linkedin.com/company/hera-biotech

Host:

Chistopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>2ef452e7-c69a-468b-8c83-cd906bc69a79Thu, 26 Mar 2026 14:01:14 GMT<p>For decades, women's health has been under-researched, underfunded, and underserved. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Somer Barburek, CEO and Co-founder of Hera Biotech, to explore how precision diagnostics and molecular innovation are starting to change that.</p><p></p><p>Somer's path to biotech founder ran through professional rodeo athletics and a firsthand understanding of how little the healthcare system was built around women's biology. At Hera Biotech, she's building a platform that uses molecular and machine-learning diagnostics to detect endometriosis earlier and more accurately, replacing invasive surgery with simple, office-based testing.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><ul><li>Why women's health has been historically underfunded and what that means for patients today</li><li>How Hera Biotech is tackling endometriosis with molecular and AI-driven diagnostics</li><li>The shift from invasive surgical diagnosis to office-based precision testing</li><li>Somer's journey from professional rodeo athlete to biotech founder</li><li>The realities of biotech commercialization and scaling a women's health company</li><li>What a more equitable, data-driven future in medicine actually looks like</li><li></li></ul><p>Who this is for: founders, clinicians, investors, and researchers in women's health, biotech diagnostics, medtech, and digital health who want to understand where precision medicine for women is headed.</p><p></p><p>Guest: </p><p>Somer Barburek, CEO and Co-founder, Hera Biotech<a rel="noopener noreferrer nofollow" href="http://www.herabiotech.com" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="http://www.herabiotech.com" target="_blank">www.herabiotech.com</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/hera-biotech" target="_blank"> </a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/hera-biotech" target="_blank">https://www.linkedin.com/company/hera-biotech</a></p><p></p><p>Host:</p><p>Chistopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank"> https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:28:4512Hera Biotech: Precision Diagnostics for Endometriosis and Women's Health | Stories in Life Sciencesfull<![CDATA[Dr. Elizabeth Pavez Lorie: Why 90% of Treatments Fail | Stories in Life Sciences]]>90% of drugs fail in clinical trials.

In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Elizabeth Pavez Lorie, CEO and Co-founder of CompreVie, to explore why that number keeps climbing and what biotech innovation can do about it.

Dr. Lorie is building human-relevant organ and tissue models that move, react, and respond like the human body, no animal models required. Her work sits at the intersection of AI-powered drug discovery, digital health, and clinical research, and she's doing it as a founder navigating the biotech funding downturn while generating early revenue through pilot testing.

In this episode of Stories in Life Sciences, we cover:

* Why 90% of drugs fail in clinical trials and what that means for pharma R&D

* How human-relevant testing models are replacing animal models in drug development

* CompreVie's approach to building advanced organ and tissue models for biotech startups

* The path from academia to entrepreneurship in life sciences

* Fundraising strategy and generating early revenue in the biotech funding downturn

* The future of AI in healthcare, clinical research innovation, and medtech

Who this is for: founders, investors, and researchers in biotech, medtech, digital health, and pharmaceutical R&D who want to understand where human-centered testing is headed.

Guest:

Dr. Elizabeth Pavez Lorie, CEO and Co-founder, CompreVie

www.comprevie.com

https://www.linkedin.com/company/comprevie

Host:

Christopher Wilson, Founder, MedAxis AI

www.medaxisai.org

https://www.linkedin.com/in/christopher-wilson-medaxisai

https://www.linkedin.com/company/medaxisai

Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.

]]>9030df80-16e7-400e-8f10-927fec072301Thu, 26 Mar 2026 13:38:24 GMT<p>90% of drugs fail in clinical trials. </p><p></p><p>In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Elizabeth Pavez Lorie, CEO and Co-founder of CompreVie, to explore why that number keeps climbing and what biotech innovation can do about it.</p><p></p><p>Dr. Lorie is building human-relevant organ and tissue models that move, react, and respond like the human body, no animal models required. Her work sits at the intersection of AI-powered drug discovery, digital health, and clinical research, and she's doing it as a founder navigating the biotech funding downturn while generating early revenue through pilot testing.</p><p></p><p>In this episode of Stories in Life Sciences, we cover:</p><p>* Why 90% of drugs fail in clinical trials and what that means for pharma R&amp;D</p><p>* How human-relevant testing models are replacing animal models in drug development</p><p>* CompreVie's approach to building advanced organ and tissue models for biotech startups</p><p>* The path from academia to entrepreneurship in life sciences</p><p>* Fundraising strategy and generating early revenue in the biotech funding downturn</p><p>* The future of AI in healthcare, clinical research innovation, and medtech</p><p></p><p>Who this is for: founders, investors, and researchers in biotech, medtech, digital health, and pharmaceutical R&amp;D who want to understand where human-centered testing is headed.</p><p></p><p>Guest:</p><p>Dr. Elizabeth Pavez Lorie, CEO and Co-founder, CompreVie</p><p><a rel="noopener noreferrer nofollow" href="http://www.comprevie.com" target="_blank">www.comprevie.com</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/comprevie" target="_blank">https://www.linkedin.com/company/comprevie</a></p><p></p><p>Host:</p><p>Christopher Wilson, Founder, MedAxis AI</p><p><a rel="noopener noreferrer nofollow" href="http://www.medaxisai.org" target="_blank">www.medaxisai.org</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/christopher-wilson-medaxisai" target="_blank">https://www.linkedin.com/in/christopher-wilson-medaxisai</a></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/medaxisai" target="_blank">https://www.linkedin.com/company/medaxisai</a></p><p></p><p>Follow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.</p>no00:57:1811Dr. Elizabeth Pavez Lorie: Why 90% of Treatments Fail | Stories in Life Sciencesfull